- Enzo Biochem (ENZB) transitions from NYSE to OTCQX Best Market.
- Trading commenced on April 21, 2025, under the symbol 'ENZB'.
- OTCQX offers cost-effective access to U.S. capital markets with transparency.
OTC Markets Group Inc. (OTCQX: OTCM) has announced that Enzo Biochem, Inc. (OTCQX: ENZB), a renowned life sciences company, has successfully shifted its trading platform from the New York Stock Exchange to the OTCQX® Best Market. This move was finalized with trading commencing under the ticker 'ENZB' on April 21, 2025.
The transition to the OTCQX Market provides Enzo Biochem with a cost-effective avenue to tap into U.S. capital markets, coupled with streamlined market requirements aimed at reducing the costs and complexities typically associated with being publicly traded. The OTCQX platform mandates participating companies to meet stringent financial criteria, adhere to best practices in corporate governance, and demonstrate robust compliance with relevant securities laws, thus ensuring transparency for investors.
CEO Kara Cannon expressed enthusiasm for the transition, highlighting that the OTCQX platform enhances investor engagement opportunities while allowing Enzo Biochem to maintain its core focus on delivering exceptional life science products and services. Enzo Biochem, with over four decades in the industry, continues to operate through its division dedicated to labeling and detection technologies, playing a crucial role in areas such as cell biology and genomics.
OTC Markets Group presently facilitates trading for approximately 12,000 U.S. and international securities, bolstered by a data-driven disclosure framework which underpins its regulated markets including the OTCQX Best Market.
